PCV33 COST ANALYSIS OF A PRIOR AUTHORIZATION PROGRAM FOR ANTI-OBESITY THERAPY IN A MEDICAID POPULATION  by Grauer, DW & Karpinski, TA
328 Abstracts
usage would be needed to identify the reasons and desired out-
comes for the use of these agents. This would also potentially
derive initiatives that might help rationalise the prescription of
these agents.
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FOR ANTI-OBESITY THERAPY IN A MEDICAID POPULATION
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OBJECTIVE: Clinical trials have demonstrated moderate thera-
peutic efﬁcacy for orlistat and sibutramine, with patients losing
between 5–10% of initial body weight. Due to the cost of orlis-
tat and sibutramine and moderate efﬁcacy, Kansas Medicaid
chose to use prior authorization to control expenditures on anti-
obesity agents. The objective of this study was to determine if
differences exist in cost and effect between patients who received
PA approval for anti-obesity therapy and those who did not.
METHODS: A retrospective, cohort study was designed in
which patients were divided into those that received PA approval
for sibutramine or orlistat and those that did not. The payer per-
spective was used in this study. Cost data included the total direct
costs incurred by the Medicaid program including medications,
physician ofﬁce visits, hospital admissions, and administrative
costs of the PA program. Effectiveness therapy was measured by
the probability of patients achieving greater than 5% loss of
initial weight. Independent sample t-tests were used to determine
if differences exist between mean costs and effectiveness between
the alternatives. RESULTS: Patients who received PA approval
for orlistat/sibutramine incurred $16,730 ± $20,185 in average
total costs over the study time period compared to $12,527 ±
$18,702 for patients who did not (p = 0.02). Average initial
weights and BMIs for patients who received drug therapy were
286 pounds and 43.4kg/m2 respectively, while patients who
didn’t had average initial weights of 255 pounds and BMI of
38.9kg/m2. Patients who received anti-obesity therapy met the
effectiveness goal 33% of the time, compared to 5% of the time
for a patient who didn’t (p < 0.001). CONCLUSION: The
average cost per Medicaid beneﬁciary was $4203 higher for
those patients who received prior authorization approval for
anti-obesity therapy compared to those who did not. However,
patients also had a signiﬁcantly higher probability of losing
weight.
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OBJECTIVE: Quality of Life instruments may be generic or
more disease speciﬁc. We were interested in disease speciﬁc
quality of life in patients following aortic valve replacement.
METHODS: We surveyed 743 patients following aortic valve
replacement surgery. The survey instruments were the SF-36 and
the Minnesota Living with Heart Failure Questionnaires.
MLwHF scores are computed by adding scores ranging from 
0 to 5 on 21 questions, yielding total summary scores of 0 to
105 with higher scores indicating poorer quality of life. All
patients were also part of an adult cardiac database that included
prospectively collected information on demographics, diagnosis
and surgical course. One-way analysis of variance (ANOVA)
tests were used to compare continuous demographic, pre-
operative, operative, and post-operative variables, and MLwHF
scores across different valve types. RESULTS: Three hundred
twenty-nine patients (43%) returned surveys. There were no dif-
ferences in age, gender or valve type received between respon-
ders and non-responders. Of the respondents, 226 were male and
103 were female. The average age was 61.8 (standard deviation
= 13.9, range 15 to 90). The majority of patients [222 (67.48%)]
received the Medtronic Freestyle stentless bioprosthetic valve, 16
(4.86%) received stented bioprosthetic valves, 56 (17.02%)
received mechanical valves, and 13 (3.95%) received homo-
grafts. The MLwHF found homograft recipients to have on
average poorer QoL (as reﬂected by higher MLwHF scores), but
these differences were not signiﬁcant. No signiﬁcant differences
were seen in MLwHF scores across valve types. Patient Mean &
Standard Deviation scores for respective categories: Physical
10.45, 10.43; Emotional 5.04, 6.23; Total 23.28, 22.71. CON-
CLUSIONS: Our study suggests that 5 to 10 years after AVR no
single valve type has a clear QoL advantage and conﬁrms pre-
vious reports that age-matched population QoL norms can be
achieved in many domains. Postulated advantages and dis-
advantages of stentless valves did not seem to have any net effect
on QoL.
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OBJECTIVE: To analyze the construct validity, criterion valid-
ity, and the acceptance and understanding of the EQ-5D in
patients with acute coronary syndromes (ACS). METHODS: All
ACS-diagnosed patients discharged from a university-afﬁliated
hospital during a 3-year period were mailed a questionnaire that
included the EQ-5D and the SF-8. The EQ-5D includes a 100-
point visual analogue scale (VAS) to measure self-reported
current health-state and ﬁve items measuring mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression. Also
included were disease severity measures [Duke Activity Status
Index (DASI), cardiac symptom count (SC), patient-perceived
cardiac disease severity], comorbidity measures (Charlson
comorbidity index, total medication count), and other demo-
graphic and disease-related items. RESULTS: Of 1217 patients,
490 (40.3%) responded. Patients averaged 65.2 (± 11.3) years
of age; 71.0% male; 91.9% Caucasian; 64.3% history of MI.
Acceptance and understanding appeared high with only
0.2%–0.4% of EQ-5D items and 8% of the VAS unanswered.
Correlations between the VAS score and DASI/SC/perceived
severity were rs = 0.741/rs = -0.615/rs = -0.455 (all p < 0.0001).
Levels of responses to EQ-5D items and the VAS score were sig-
niﬁcantly better for patients with very mild/mild perceived
disease severity compared to severe/very severe, and for patients
with a DASI ≥ 18 compared to a DASI < 18. VAS score and 
SF-8 subscale score correlation coefﬁcients ranged from
0.526–0.764 (all p < 0.0001). Signiﬁcant differences were
observed between the response level of individual EQ-5D items
and scores of comparable SF-8 subscales. The nine most common
health states were identiﬁed based on the ﬁve EQ-5D item scores.
As health status diminished there was a decline in the VAS, DASI
and satisfaction with current health state, and an increase in the
perceived severity, comorbidity score, SC, and medication count.
